Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 135

1.

A novel approach to the discovery of survival biomarkers in glioblastoma using a joint analysis of DNA methylation and gene expression.

Smith AA, Huang YT, Eliot M, Houseman EA, Marsit CJ, Wiencke JK, Kelsey KT.

Epigenetics. 2014 Jun;9(6):873-83. doi: 10.4161/epi.28571. Epub 2014 Mar 26.

2.

The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone.

Molenaar RJ, Verbaan D, Lamba S, Zanon C, Jeuken JW, Boots-Sprenger SH, Wesseling P, Hulsebos TJ, Troost D, van Tilborg AA, Leenstra S, Vandertop WP, Bardelli A, van Noorden CJ, Bleeker FE.

Neuro Oncol. 2014 Sep;16(9):1263-73. doi: 10.1093/neuonc/nou005. Epub 2014 Feb 6.

3.

Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation.

Jha P, Pia Patric IR, Shukla S, Pathak P, Pal J, Sharma V, Thinagararanjan S, Santosh V, Suri V, Sharma MC, Arivazhagan A, Suri A, Gupta D, Somasundaram K, Sarkar C.

Neuro Oncol. 2014 Dec;16(12):1607-17. doi: 10.1093/neuonc/nou113. Epub 2014 Jul 4.

4.

Genetic, epigenetic, and molecular landscapes of multifocal and multicentric glioblastoma.

Liu Q, Liu Y, Li W, Wang X, Sawaya R, Lang FF, Yung WK, Chen K, Fuller GN, Zhang W.

Acta Neuropathol. 2015 Oct;130(4):587-97. doi: 10.1007/s00401-015-1470-8. Epub 2015 Sep 1.

5.

Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.

Chou AP, Chowdhury R, Li S, Chen W, Kim AJ, Piccioni DE, Selfridge JM, Mody RR, Chang S, Lalezari S, Lin J, Sanchez DE, Wilson RW, Garrett MC, Harry B, Mottahedeh J, Nghiemphu PL, Kornblum HI, Mischel PS, Prins RM, Yong WH, Cloughesy T, Nelson SF, Liau LM, Lai A.

J Natl Cancer Inst. 2012 Oct 3;104(19):1458-69. doi: 10.1093/jnci/djs357. Epub 2012 Sep 3.

6.

LOC283731 promoter hypermethylation prognosticates survival after radiochemotherapy in IDH1 wild-type glioblastoma patients.

Mock A, Geisenberger C, Orlik C, Warta R, Schwager C, Jungk C, Dutruel C, Geiselhart L, Weichenhan D, Zucknick M, Nied AK, Friauf S, Exner J, Capper D, Hartmann C, Lahrmann B, Grabe N, Debus J, von Deimling A, Popanda O, Plass C, Unterberg A, Abdollahi A, Schmezer P, Herold-Mende C.

Int J Cancer. 2016 Jul 15;139(2):424-32. doi: 10.1002/ijc.30069. Epub 2016 Mar 18.

7.

Molecular Predictors of Long-Term Survival in Glioblastoma Multiforme Patients.

Lu J, Cowperthwaite MC, Burnett MG, Shpak M.

PLoS One. 2016 Apr 28;11(4):e0154313. doi: 10.1371/journal.pone.0154313. eCollection 2016.

8.

Relationship between tumor enhancement, edema, IDH1 mutational status, MGMT promoter methylation, and survival in glioblastoma.

Carrillo JA, Lai A, Nghiemphu PL, Kim HJ, Phillips HS, Kharbanda S, Moftakhar P, Lalaezari S, Yong W, Ellingson BM, Cloughesy TF, Pope WB.

AJNR Am J Neuroradiol. 2012 Aug;33(7):1349-55. doi: 10.3174/ajnr.A2950. Epub 2012 Feb 9.

9.

Molecular subtypes of glioma identified by genome-wide methylation profiling.

Kloosterhof NK, de Rooi JJ, Kros M, Eilers PH, Sillevis Smitt PA, van den Bent MJ, French PJ.

Genes Chromosomes Cancer. 2013 Jul;52(7):665-74. doi: 10.1002/gcc.22062. Epub 2013 Apr 30.

PMID:
23629961
10.

Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age.

Lötsch D, Ghanim B, Laaber M, Wurm G, Weis S, Lenz S, Webersinke G, Pichler J, Berger W, Spiegl-Kreinecker S.

Neuro Oncol. 2013 Apr;15(4):423-32. doi: 10.1093/neuonc/nos329. Epub 2013 Feb 7.

11.

Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.

Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, Loeffler M, Reifenberger G, Pietsch T, von Deimling A, Weller M; German Glioma Network.

Clin Cancer Res. 2013 Sep 15;19(18):5146-57. doi: 10.1158/1078-0432.CCR-13-0017. Epub 2013 Aug 5.

12.

Outcome and molecular characteristics of adolescent and young adult patients with newly diagnosed primary glioblastoma: a study of the Society of Austrian Neurooncology (SANO).

Leibetseder A, Ackerl M, Flechl B, Wöhrer A, Widhalm G, Dieckmann K, Kreinecker SS, Pichler J, Hainfellner J, Preusser M, Marosi C.

Neuro Oncol. 2013 Jan;15(1):112-21. doi: 10.1093/neuonc/nos283. Epub 2012 Dec 7.

13.

Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.

Zhang J, Yang JH, Quan J, Kang X, Wang HJ, Dai PG.

Tumour Biol. 2016 Oct;37(10):13571-13579. Epub 2016 Jul 28.

PMID:
27468718
14.

A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.

Cheng W, Ren X, Cai J, Zhang C, Li M, Wang K, Liu Y, Han S, Wu A.

Oncotarget. 2015 Oct 6;6(30):29285-95. doi: 10.18632/oncotarget.4978.

15.

IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.

Kalkan R, Atli Eİ, Özdemir M, Çiftçi E, Aydin HE, Artan S, Arslantaş A.

Gene. 2015 Jan 1;554(1):81-6. doi: 10.1016/j.gene.2014.10.027. Epub 2014 Oct 14.

PMID:
25455102
16.

Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective.

Wiestler B, Claus R, Hartlieb SA, Schliesser MG, Weiss EK, Hielscher T, Platten M, Dittmann LM, Meisner C, Felsberg J, Happold C, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Grimm C, Weichenhan D, Tews B, Reifenberger G, Capper D, Müller W, Plass C, Weller M, Wick W; Neuro-oncology Working Group (NOA) of the German Cancer Society.

Neuro Oncol. 2013 Aug;15(8):1017-26. doi: 10.1093/neuonc/not043. Epub 2013 Apr 17.

17.

Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.

Weller M, Felsberg J, Hartmann C, Berger H, Steinbach JP, Schramm J, Westphal M, Schackert G, Simon M, Tonn JC, Heese O, Krex D, Nikkhah G, Pietsch T, Wiestler O, Reifenberger G, von Deimling A, Loeffler M.

J Clin Oncol. 2009 Dec 1;27(34):5743-50. doi: 10.1200/JCO.2009.23.0805. Epub 2009 Oct 5.

PMID:
19805672
18.

Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.

Kawasoe T, Takeshima H, Yamashita S, Mizuguchi S, Fukushima T, Yokogami K, Yamasaki K.

J Neurosurg. 2015 Feb;122(2):317-23. doi: 10.3171/2014.10.JNS132159. Epub 2014 Nov 21.

PMID:
25415071
19.

Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.

Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H, Kuratsu J.

World J Surg Oncol. 2013 Oct 25;11:284. doi: 10.1186/1477-7819-11-284.

20.

Correlation between the prognostic value and the expression of the stem cell marker CD133 and isocitrate dehydrogenase1 in glioblastomas.

Shin JH, Lee YS, Hong YK, Kang CS.

J Neurooncol. 2013 Dec;115(3):333-41. doi: 10.1007/s11060-013-1234-z. Epub 2013 Oct 16.

PMID:
24129546

Supplemental Content

Support Center